Detalhe da pesquisa
1.
Randomized phase II BGOG/ENGOT-cx1 study of paclitaxel-carboplatin with or without nintedanib in first-line recurrent or advanced cervical cancer.
Gynecol Oncol
; 174: 80-88, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37167896
2.
Influence of migrant background on patient preference and expectations in breast and gynecological malignancies (NOGGO-expression V study): results of a prospective multicentre study in 606 patients in Germany.
BMC Cancer
; 21(1): 1018, 2021 Sep 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34511112
3.
Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base.
Gynecol Oncol
; 154(3): 539-546, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31230821
4.
Statistical controversies in clinical research: the importance of importance.
Ann Oncol
; 27(7): 1185-9, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27052655
5.
Polymorphism of the IL-8 gene and the risk of ovarian cancer.
Cytokine
; 71(2): 334-8, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25151495
6.
Role of serum concentration of VEGFR1 and TIMP2 on clinical outcome in primary cervical cancer: results of a companion protocol of the randomized, NOGGO-AGO phase III adjuvant trial of simultaneous cisplatin-based radiochemotherapy vs. carboplatin and paclitaxel containing sequential radiotherapy.
Cytokine
; 61(3): 755-8, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23415672
7.
Preoperative HE4 expression in plasma predicts surgical outcome in primary ovarian cancer patients: results from the OVCAD study.
Gynecol Oncol
; 128(2): 245-51, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23178313
8.
Feasibility of surgery after systemic treatment with the humanized recombinant antibody bevacizumab in heavily pretreated patients with advanced epithelial ovarian cancer.
Ann Surg Oncol
; 19(4): 1326-33, 2012 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-22090022
9.
Role of histological type on surgical outcome and survival following radical primary tumour debulking of epithelial ovarian, fallopian tube and peritoneal cancers.
Br J Cancer
; 105(12): 1818-24, 2011 Dec 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-22045193
10.
Δ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer.
Br J Cancer
; 105(10): 1593-9, 2011 Nov 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-22009029
11.
Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort.
Br J Cancer
; 105(7): 890-6, 2011 Sep 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-21878937
12.
Adult granulosa cell tumors of the ovary: tumor dissemination pattern at primary and recurrent situation, surgical outcome.
Gynecol Oncol
; 119(2): 285-90, 2010 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-20637497
13.
Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer.
Cytokine
; 42(1): 77-84, 2008 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-18329282
14.
PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives.
Geburtshilfe Frauenheilkd
; 76(2): 164-169, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26941449
15.
BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients--a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD).
Eur J Cancer
; 50(12): 2090-8, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24889916
16.
Clinical experience of young patients with small cell ovarian carcinoma of the hypercalcemic type (OSCCHT).
Eur J Obstet Gynecol Reprod Biol
; 165(2): 313-7, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-22906684
17.
Can complete tumor resection be predicted in advanced primary epithelial ovarian cancer? A systematic evaluation of 360 consecutive patients.
Eur J Surg Oncol
; 36(12): 1202-10, 2010 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-20864305